No benefit of Interfant protocols compared to BFM‐based protocols for infants with acute lymphoblastic leukemia. Results from an institution in Argentina-Reference-Cited by-同舟云学术

No benefit of Interfant protocols compared to BFM‐based protocols for infants with acute lymphoblastic leukemia. Results from an institution in Argentina

Published:2020-07-30 Issue:10 Volume:67 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Pennella Carla L.¹^ORCID,Deu María A.¹,Rossi Jorge G.²,Baialardo Edgardo M.³,Alonso Cristina N.¹,Rubio Patricia¹,Guitter Myriam R.¹,La Rosa Cristian G. Sánchez¹,Alfaro Elizabeth M.¹,Zubizarreta Pedro A.¹,Felice María S.¹

Affiliation:

1. Department of Hematology‐Oncology Hospital de Pediatría S.A.M.I.C Prof. Dr. Juan P. Garrahan Buenos Aires Argentina

2. Department of Immunology and Rheumatology Hospital de Pediatría S.A.M.I.C Prof. Dr. Juan P. Garrahan Buenos Aires Argentina

3. Department of Genetics Hospital de Pediatría S.A.M.I.C Prof. Dr. Juan P. Garrahan Buenos Aires Argentina

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.28624

Reference39 articles.

1. Prednisone Response Is the Strongest Predictor of Treatment Outcome in Infant Acute Lymphoblastic Leukemia

2. Infant acute lymphoblastic leukemia: Lessons learned and future directions

3. Recent progress in the treatment of infant acute lymphoblastic leukemia

4. Biological and therapeutic aspects of infant leukemia

5. Treatment of infant leukemias: challenge and promise

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acute Lymphoblastic Leukaemia in the Youngest: Haematopoietic Stem Cell Transplantation and Beyond;Frontiers in Pediatrics;2022-02-24